First iPS cell licences granted in Japan
This article was originally published in Scrip
A venture firm under Japan's Kyoto University has licensed to two domestic companies technology relating to induced pluripotent stem (iPS) cells. The move marks the first step towards the commercialisation of research in the field, where Japan has a leading position.
You may also be interested in...
First-line lung cancer approval will expand potential market for Takeda's ALK contender but the latecomer is also facing some well-established class competition in the setting.
US venture raises new funds from Asia partners as it builds a direct presence in China to develop its oncology portfolio.
Novartis gene therapy gets insurance coverage at record price although small patient population will limit system costs.